Mirum Pharmaceuticals is a biopharmaceutical company focused on the identification, acquisition, development and commercialization of therapies for rare and orphan diseases. Co.'s focus is the development and commercialization of LIVMARLI® (maralixibat) oral solution (Livmarli) and volixibat. Livmarli is an oral solution approved as a once daily medicine for cholestatic pruritus in patients with Alagille syndrome one year of age and older. Co.'s second product candidate, volixibat, an oral, minimally-absorbed agent designed to inhibit ileal bile acid transporter, for the treatment of adult patients with cholestatic liver diseases. The MIRM average annual return since 2019 is shown above.
The Average Annual Return on the MIRM average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MIRM average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MIRM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|